Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity in reach for all people.
Jamie Bay Nishi, director of GHTC, was quoted in a Devex article focused on the new antimicrobial innovation hub in Germany.
Brink News picked up GE Report's article by GHTC Director Jamie Bay Nishi. The article highlights findings from the coalition's report Return on innovation: Why global health R&D is a smart investment for the United States.
In countries like Kenya, some of the most incredible global health research is taking place to develop new drugs, vaccines, diagnostics and other health products. In addition, previous research has lead to the roll-out of lifesaving health tools such as HIV/AIDS drugs, vaccines to protect children from pneumonia, and insecticide-treated bednets to prevent malaria.
Earlier today, the fourth annual G-FINDER report was released. This resource, developed by Policy Cures, is the only one of its kind that maps the global level of investment in developing new vaccines, drugs, diagnostics, and other tools that address 31 neglected diseases. This year’s report studies funding levels and trends in 2010.
